

**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
<b>CBC; Complete Blood Count</b>			
Hemoglobin (Hb)* Method : Cynmeth Photometric Measurement	13.6	12.0 - 15.0	gm/dL
Erythrocyte (RBC) Count* Method : Electrical Impedence	4.7	3.8 - 4.8	mil/cu.mm
Packed Cell Volume (PCV)* Method : Calculated	42	36 - 46	%
Mean Cell Volume (MCV)* Method : Electrical Impedence	90	83 - 101	fL
Mean Cell Haemoglobin (MCH)* Method : Calculated	29	27 - 32	pg
Mean Corpuscular Hb Concn. (MCHC)* Method : Calculated	31.9	31.5 - 34.5	gm/dL
Red Cell Distribution Width (RDW)* Method : Electrical Impedence	13.4	11.6 - 14.0	%
Total Leucocytes (WBC) Count* Method : Electrical Impedence	8400	4000-10000	cell/cu.mm
Neutrophils* Method : VCSn Technology	49	40 - 80	%
Lymphocytes* Method : VCSn Technology	44	20 - 40	%
Monocytes* Method : VCSn Technology	6	2 - 10	%
Eosinophils* Method : VCSn Technology	1	1 - 6	%
Basophils	0	0 - 1	
Platelet Count* Method : Electrical Impedence	2.58	1.5 - 4.5	10 <sup>3</sup> /ul
Mean Platelet Volume (MPV)* Method : Electrical Impedence	8.1	7.2 - 11.7	fL

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
PCT*	0.2	0.2 - 0.5	%
Method : Calculated			
PDW*	17.7	9.0 - 17.0	%
Method : Calculated			

Tests done on Automated Three Part Cell Counter. (WBC, RBC, Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.

### Esr, Erythrocyte Sedimentation Rate

**Esr, Erythrocyte Sedimentation Rate (Westergren)**                      **31**                      0-30                      mm/hr

#### **Interpretation:**

- It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

### Blood Group & Rh Type

**Blood Grouping & Rh Typing**    **"B" + (POSITIVE)**

Method : Forward and Reverse By Tube Method

#### **Methodology**

This is done by forward and reverse grouping by tube Agglutination method.

#### **Interpretation**

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2-4 years).

Dr. CH. Deepthi Chandrika  
M.D. Pathology  
Reg.No. APCM/FMR/77174

Approved by

Scan to Validate



Patient Name : MRS. M. THARMILA RANI

Age / Gender : 31 years / Female

Patient ID : 8363

Source : MEDI WHEEL

Referral : SELF

Collection Time : Aug 19, 2022, 02:04 p.m.

Reporting Time : Aug 19, 2022, 05:37 p.m.

Sample ID :



004323122P

Test Description	Value(s)	Reference Range	Unit
<b><u>Fasting - Glucose</u></b>			
<b>Glucose Fasting*</b> Method : Plasma, Hexokinase	73	Normal: 70-110 Impaired Fasting Glucose (IFG): 110-125 Diabetes Mellitus: >= 126 (On more than one occasion) (American Diabetes Association guidelines 2017)	mg/dL
<b><u>Fasting Urine Sugar</u></b>			
Fasting Urine Sugar	NEGATIVE	NEGATIVE -	
<b><u>Lipid Profile</u></b>			
<b>Cholesterol-Total</b> Method : Serum, Cholesterol oxidase esterase, peroxidase	125	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	mg/dL
<b>Triglycerides</b> Method : Serum, Enzymatic, endpoint	89	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
<b>Cholesterol-HDL Direct</b> Method : Serum, Direct measure-PEG	45	Normal: > 40 Major Heart Risk: < 40	mg/dL

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
LDL Cholesterol Method : Serum	62.2	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	mg/dL
Non - HDL Cholesterol, Serum Method : calculated	80	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	mg/dL
VLDL Cholesterol Method : calculated	17.8	6 - 38	mg/dL
CHOL/HDL RATIO Method : calculated	<b>2.78</b>	3.5 - 5.0	ratio
LDL/HDL RATIO Method : calculated	1.38	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	ratio
HDL/LDL RATIO Method : calculated	0.7	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	ratio

**Note:** 8-10 hours fasting sample is required.

### **Liver Function Test**

Bilirubin - Total Method : Serum, Diazotization	0.6	Adults and Children: < 1.2	mg/dL
Bilirubin - Direct Method : Serum, Diazotization	0.2	Adults and Children: < 0.5	mg/dL
Bilirubin - Indirect Method : Serum, Calculated	0.4	0.1 - 1.0	mg/dL

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
SGOT Method : Serum, UV with P5P, IFCC 37 degree	28	< 50	U/L
SGPT Method : Serum, UV with P5P, IFCC 37 degree	22	< 50	U/L
Alkaline Phosphatase-ALPI Method : Serum, PNPP, AMP Buffer, IFCC 37 degree	58	30-120	U/L
Total Protein Method : Serum, Biuret, reagent blank end point	7.7	6.6 - 8.3	g/dL
Globulin Method : Calculated	3.4	1.8 - 3.6	g/dL
Albumin Method : Serum, Bromocresol purple	4.3	Adults: 3.5 - 5.2	g/dL
A/G Ratio Method : Calculated	1.26	1.2 - 2.2	ratio
GGT-Gamma Glutamyl Transpeptidase Method : Serum, G-glutamyl-carboxy-nitroanilide	18	< 55	U/L

### **KIDNEY FUNCTION TEST**

Urea * Method : Serum	20	15- 50	mg/dL
Blood Urea Nitrogen-BUN* Method : Serum, Urease	9.3	7 - 24	mg/dL
Uric Acid* Method : Serum, Uricase/POD	4.9	3.5 - 7.2	mg/dL
Creatinine* Method : Serum, Jaffe IDMS	0.7	0.6 - 1.1	mg/dL

### **Urine Routine**

Colour*	Pale Yellow	Pale Yellow
Transparency (Appearance)*	Clear	Clear

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
Deposit*	Absent	Absent	
Reaction (pH)*	5.0	4.5 - 8	
Specific Gravity*	1.025	1.010 - 1.030	
<b><u>Chemical Examination (Automated Dipstick Method) Urine</u></b>			
Urine Glucose (sugar)*	Absent	Absent	
Urine Protein (Albumin)*	Absent	Absent	
Urine Ketones (Acetone)*	Absent	Absent	
Blood*	Absent	Absent	
Bile pigments*	Absent	Absent	
Nitrite*	Absent	Absent	
Urobilinogen*	Normal	Normal	
<b><u>Microscopic Examination Urine</u></b>			
Pus Cells (WBCs)*	2-3	0 - 5	/hpf
Epithelial Cells*	0-1	0 - 4	/hpf
Red blood Cells*	Absent	Absent	/hpf
Crystals*	Absent	Absent	
Cast*	Absent	Absent	
Trichomonas Vaginalis*	Absent	Absent	
Yeast Cells*	Absent	Absent	
Amorphous deposits*	Absent	Absent	
Bacteria*	Absent	Absent	

**HBA1C (Glycosylated Haemoglobin)**

Glyco Hb (HbA1C)	5.2	Non-Diabetic: <=5.9 Pre Diabetic:6.0-6.4 Diabetic: >=6.5	%
Method : EDTA Whole blood,HPLC			

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



**Patient Name :** MRS. M. THARMILA RANI

**Age / Gender :** 31 years / Female

**Patient ID :** 8363

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Aug 19, 2022, 02:04 p.m.

**Reporting Time :** Aug 19, 2022, 05:37 p.m.

**Sample ID :**



004323122P

Test Description	Value(s)	Reference Range	Unit
Estimated Average Glucose :	102		mg/dL

**Interpretations**

- HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
- Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- In known diabetic patients, following values can be considered as a tool for monitoring the glycemc control.  
Excellent control-6-7 %  
Fair to Good control – 7-8 %  
Unsatisfactory control – 8 to 10 %  
Poor Control – More than 10 %

**Thyroid Function Test ( TFT)**

THYROID STIMULATING HORMONE (TSH) Method : CLIA	7.0	<b>0.46 – 8.10 : 1 Yrs – 5 Yrs</b> <b>0.36 – 5.80 : 6 Yrs – 18 Yrs</b> <b>0.35 – 5.50 : 18 Yrs – 55 Yrs</b> <b>0.50 – 8.90 : &gt;55 Yrs</b> <b>Pregnancy Ranges::::</b> <b>Ist Tri :0.1 - 2.5</b> <b>IIInd Tri :0.2 - 3.0</b> <b>IIIrd Tri:0.3 - 3.0</b>	uIU/mL
TOTAL TRIIODOTHYRONINE (T3) Method : CLIA	132	<b>126 – 258 : 1 Yr – 5 Yr</b> <b>96 – 227 : 6 Yr – 15 Yr</b> <b>91 – 164 : 16 Yr – 18 Yr</b> <b>60 – 181 : &gt; 18 Years</b> <b>Pregnancy :</b> <b>1st Trimester : 81 - 190</b> <b>2nd &amp; 3rd Trimester:100 - 260</b>	ng/dl

Dr.CH.Deepthi Chandrika  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



